Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:33 PM
Ignite Modification Date:
2025-12-24 @ 7:33 PM
NCT ID:
NCT01789203
Eligibility Criteria:
Inclusion Criteria:
* Male or female subjects over the age of 18 years
* Recipients of a primary or repeat renal allograft either alone (from a deceased or living donor) or as a dual-kidney transplant
* Signed informed consent form prior to any research assessment
Exclusion Criteria:
* Patients with known severe allergy to ciprofloxacin
* History of tendon rupture or tendinitis
* Use of antiarrythmic drugs known to prolong the QT interval such as class IA antiarrhythmic drugs (e.g. quinidine, procainamide, disopyramide), class III antiarrhythmic drugs (e.g. amiodarone, sotalol)
* Patients with history of previous non-renal transplantation
* Recipients administered rituximab within one year prior to transplantation, or recipients expected to receive rituximab as part of desensitization strategy or for the presence of historical donor specific antibodies
* QTc interval interval of greater than 500 msec on admission or post-operative EKG
* BK nephropathy with previous transplant
* BK viremia on admission
* Any condition present during the initial transplant hospitalization that in the investigator's judgment would increase the risk associated with participation in the study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01789203
Study Brief:
Protocol Section:
NCT01789203